CECOG Academy

www.cecog.org

 

CECOG Academy
T

New 2022 ESMO Guidelines for Pancreatic Cancer

By CECOG Academy FEATURING Thierry Conroy
By CECOG Academy FEATURING Thierry Conroy
0 views
September 7, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

03:57
Lilly Medical Affairs

Resistance Mechanisms to ET, Including ESR1 Mutations in HR+, HER2- …

Feat. K. Jhaveri

Featured Video

05:59
Lilly Medical Affairs

Progression on First-Line Therapy in HR+, HER2- MBC: Treatments and …

Feat. J. O’Shaughnessy
Pancreas Cancer Academy 2022
10:15
CECOG Academy

Case Review of a 78 y/o Man With PDAC: Following OS From the Start o…

Feat. F. Huemer
14:55
CECOG Academy

Case Review: Fit Patient With mPDAC

Feat. H. Taghizadeh
18:58
CECOG Academy

1L mPDAC & Sequence Debate: Why Gemcitabine & Nab-Paclitaxel…

Feat. H. Wasan
18:36
CECOG Academy

mPDAC Treatment Debate: FOLFIRINOX Followed by Gemcitabine + Nab-Pac…

Feat. J. Taieb
23:12
CECOG Academy

mPDAC Sequence Debate: Albumin-Bound Paclitaxel / Gemcitabine Follow…

Feat. G. Prager
26:54
CECOG Academy

New 2022 ESMO Guidelines for Pancreatic Cancer

Feat. T. Conroy
08:41
CECOG Academy

Case Review: Borderline Resectable PDAC

Feat. H. Taghizadeh
22:45
CECOG Academy

Borderline PDAC: What Is the Best Neoadjuvant Treatment Concept?

Feat. T. Macarulla
17:52
CECOG Academy

What to Do With PDAC Patients After Secondary Resection?

Feat. H. Wasan
31:42
CECOG Academy

How to Assess Resectability: The Surgeon's View

Feat. O. Strobel
23:05
CECOG Academy

How to Pick the Individual (Neo)adjuvant Treatment Concept in Resect…

Feat. E. Van Cutsem
27:28
CECOG Academy

Personalized Treatment Approach by Molecular Profiling Might Lead to…

Feat. T. Golan